Denali Therapeutics Inc at Stifel CNS Days (Virtual) Transcript
Great, thank you very much. It's always a pleasure to be moderating a panel with Ryan Watts, CEO and Founder of Denali. Obviously you have a ton going on at Denali as well. So, maybe, Ryan, sort of give a quick overview and update on your various key programs and then we can make it more conversational. So, thank you again.
Thanks again for the invitation. I think this is the third or fourth year in a row that I have been at a CNS day and what an interesting time to have a CNS day and to talk about an enormous unmet need with Alzheimer's, Parkinson's, ALS. In the case of Denali, we also go after some rare neurodegenerative diseases or diseases that have neurodegenerative components such as lysosomal storage diseases.
And I think it's an exciting time, it's a challenging area, no doubt. And for us, we've approached it really with three principles. So, for us the first principle is what we call the degenogene pathway. So, genes when mutated that cause neurodegeneration.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |